265 related articles for article (PubMed ID: 23300607)
1. PG545, a heparan sulfate mimetic, reduces heparanase expression in vivo, blocks spontaneous metastases and enhances overall survival in the 4T1 breast carcinoma model.
Hammond E; Brandt R; Dredge K
PLoS One; 2012; 7(12):e52175. PubMed ID: 23300607
[TBL] [Abstract][Full Text] [Related]
2. PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models.
Dredge K; Hammond E; Handley P; Gonda TJ; Smith MT; Vincent C; Brandt R; Ferro V; Bytheway I
Br J Cancer; 2011 Feb; 104(4):635-42. PubMed ID: 21285983
[TBL] [Abstract][Full Text] [Related]
3. The heparanase inhibitor PG545 is a potent anti-lymphoma drug: Mode of action.
Weissmann M; Bhattacharya U; Feld S; Hammond E; Ilan N; Vlodavsky I
Matrix Biol; 2019 Apr; 77():58-72. PubMed ID: 30096360
[TBL] [Abstract][Full Text] [Related]
4. PG545, an angiogenesis and heparanase inhibitor, reduces primary tumor growth and metastasis in experimental pancreatic cancer.
Ostapoff KT; Awasthi N; Cenik BK; Hinz S; Dredge K; Schwarz RE; Brekken RA
Mol Cancer Ther; 2013 Jul; 12(7):1190-201. PubMed ID: 23696215
[TBL] [Abstract][Full Text] [Related]
5. Immunomodulatory Activities of the Heparan Sulfate Mimetic PG545.
Bendersky V; Yang Y; Brennan TV
Adv Exp Med Biol; 2020; 1221():461-470. PubMed ID: 32274722
[TBL] [Abstract][Full Text] [Related]
6. Heparanase Inhibition by Pixatimod (PG545): Basic Aspects and Future Perspectives.
Hammond E; Dredge K
Adv Exp Med Biol; 2020; 1221():539-565. PubMed ID: 32274726
[TBL] [Abstract][Full Text] [Related]
7. Involvement of Heparanase in the Pathogenesis of Mesothelioma: Basic Aspects and Clinical Applications.
Barash U; Lapidot M; Zohar Y; Loomis C; Moreira A; Feld S; Goparaju C; Yang H; Hammond E; Zhang G; Li JP; Ilan N; Nagler A; Pass HI; Vlodavsky I
J Natl Cancer Inst; 2018 Oct; 110(10):1102-1114. PubMed ID: 29579286
[TBL] [Abstract][Full Text] [Related]
8. The heparan sulfate mimetic PG545 interferes with Wnt/β-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabine.
Jung DB; Yun M; Kim EO; Kim J; Kim B; Jung JH; Wang E; Mukhopadhyay D; Hammond E; Dredge K; Shridhar V; Kim SH
Oncotarget; 2015 Mar; 6(7):4992-5004. PubMed ID: 25669977
[TBL] [Abstract][Full Text] [Related]
9. Oligosaccharides from fucosylated glycosaminoglycan prevent breast cancer metastasis in mice by inhibiting heparanase activity and angiogenesis.
Zhou L; Yin R; Gao N; Sun H; Chen D; Cai Y; Ren L; Yang L; Zuo Z; Zhang H; Zhao J
Pharmacol Res; 2021 Apr; 166():105527. PubMed ID: 33667689
[TBL] [Abstract][Full Text] [Related]
10. Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis.
Edovitsky E; Elkin M; Zcharia E; Peretz T; Vlodavsky I
J Natl Cancer Inst; 2004 Aug; 96(16):1219-30. PubMed ID: 15316057
[TBL] [Abstract][Full Text] [Related]
11. The Heparanase Inhibitor PG545 Attenuates Colon Cancer Initiation and Growth, Associating with Increased p21 Expression.
Singh P; Blatt A; Feld S; Zohar Y; Saadi E; Barki-Harrington L; Hammond E; Ilan N; Vlodavsky I; Chowers Y; Half E
Neoplasia; 2017 Mar; 19(3):175-184. PubMed ID: 28147305
[TBL] [Abstract][Full Text] [Related]
12. Heparan sulfate mimetic PG545-mediated antilymphoma effects require TLR9-dependent NK cell activation.
Brennan TV; Lin L; Brandstadter JD; Rendell VR; Dredge K; Huang X; Yang Y
J Clin Invest; 2016 Jan; 126(1):207-19. PubMed ID: 26649979
[TBL] [Abstract][Full Text] [Related]
13. PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples.
Winterhoff B; Freyer L; Hammond E; Giri S; Mondal S; Roy D; Teoman A; Mullany SA; Hoffmann R; von Bismarck A; Chien J; Block MS; Millward M; Bampton D; Dredge K; Shridhar V
Eur J Cancer; 2015 May; 51(7):879-892. PubMed ID: 25754234
[TBL] [Abstract][Full Text] [Related]
14. Specific Inhibition of Heparanase by a Glycopolymer with Well-Defined Sulfation Pattern Prevents Breast Cancer Metastasis in Mice.
Loka RS; Sletten ET; Barash U; Vlodavsky I; Nguyen HM
ACS Appl Mater Interfaces; 2019 Jan; 11(1):244-254. PubMed ID: 30543095
[TBL] [Abstract][Full Text] [Related]
15. The Heparan Sulfate Mimetic PG545 Modulates T Cell Responses and Prevents Delayed-Type Hypersensitivity.
Koliesnik IO; Kuipers HF; Medina CO; Zihsler S; Liu D; Van Belleghem JD; Bollyky PL
Front Immunol; 2020; 11():132. PubMed ID: 32117279
[TBL] [Abstract][Full Text] [Related]
16. Heparanase inhibition attenuates atherosclerosis progression and liver steatosis in E
Muhammad RS; Abu-Saleh N; Kinaneh S; Agbaria M; Sabo E; Grajeda-Iglesias C; Volkova N; Hamoud S
Atherosclerosis; 2018 Sep; 276():155-162. PubMed ID: 30075439
[TBL] [Abstract][Full Text] [Related]
17. Structural Insights into Pixatimod (PG545) Inhibition of Heparanase, a Key Enzyme in Cancer and Viral Infections.
Chhabra M; Wilson JC; Wu L; Davies GJ; Gandhi NS; Ferro V
Chemistry; 2022 Feb; 28(11):e202104222. PubMed ID: 34981584
[TBL] [Abstract][Full Text] [Related]
18. Oligomannurarate sulfate, a novel heparanase inhibitor simultaneously targeting basic fibroblast growth factor, combats tumor angiogenesis and metastasis.
Zhao H; Liu H; Chen Y; Xin X; Li J; Hou Y; Zhang Z; Zhang X; Xie C; Geng M; Ding J
Cancer Res; 2006 Sep; 66(17):8779-87. PubMed ID: 16951194
[TBL] [Abstract][Full Text] [Related]
19. PI-88 and Related Heparan Sulfate Mimetics.
Chhabra M; Ferro V
Adv Exp Med Biol; 2020; 1221():473-491. PubMed ID: 32274723
[TBL] [Abstract][Full Text] [Related]
20. Discovery of PG545: a highly potent and simultaneous inhibitor of angiogenesis, tumor growth, and metastasis.
Ferro V; Liu L; Johnstone KD; Wimmer N; Karoli T; Handley P; Rowley J; Dredge K; Li CP; Hammond E; Davis K; Sarimaa L; Harenberg J; Bytheway I
J Med Chem; 2012 Apr; 55(8):3804-13. PubMed ID: 22458531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
